Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
0.3834
Dollar change
-0.0325
Percentage change
-7.81
%
Index- P/E- EPS (ttm)- Insider Own49.45% Shs Outstand78.31M Perf Week72.94%
Market Cap30.02M Forward P/E- EPS next Y-0.38 Insider Trans-0.02% Shs Float39.59M Perf Month40.54%
Income- PEG- EPS next Q-0.17 Inst Own39.48% Short Float0.12% Perf Quarter-18.43%
Sales- P/S- EPS this Y30.20% Inst Trans19.80% Short Ratio0.02 Perf Half Y-61.27%
Book/sh0.88 P/B0.43 EPS next Y26.92% ROA- Short Interest0.05M Perf Year-76.76%
Cash/sh1.11 P/C0.35 EPS next 5Y- ROE- 52W Range0.19 - 2.08 Perf YTD-21.29%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-81.57% Beta2.08
Dividend TTM- Quick Ratio6.95 Sales past 5Y- Gross Margin- 52W Low100.52% ATR (14)0.07
Dividend Ex-Date- Current Ratio6.95 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)60.55 Volatility28.76% 15.67%
Employees- Debt/Eq0.22 Sales Y/Y TTM- Profit Margin- Recom2.00 Target Price0.65
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q-54.96% Payout- Rel Volume0.43 Prev Close0.42
Sales Surprise-6.38% EPS Surprise0.00% Sales Q/Q- EarningsFeb 29 AMC Avg Volume2.37M Price0.38
SMA2043.28% SMA5010.16% SMA200-47.78% Trades Volume1,015,939 Change-7.81%
Date Action Analyst Rating Change Price Target Change
Nov-18-22Initiated BofA Securities Neutral $2
Oct-25-22Initiated Credit Suisse Outperform $5
Sep-06-22Initiated Cowen Outperform
Today 04:01PM
Feb-27-24 02:00AM
Feb-26-24 01:51PM
08:47AM
Feb-21-24 04:05PM
09:55AM Loading…
Jan-15-24 09:55AM
Dec-29-23 08:22AM
Dec-21-23 12:00PM
Dec-18-23 08:00AM
Nov-13-23 09:36AM
Nov-09-23 04:02PM
Oct-19-23 12:27PM
Oct-12-23 08:00AM
Oct-06-23 07:00AM
Sep-21-23 08:00AM
03:03AM Loading…
Sep-15-23 03:03AM
Sep-13-23 01:16PM
08:00AM
Aug-14-23 09:26AM
Aug-11-23 06:43AM
Aug-10-23 04:01PM
Jul-10-23 07:00AM
Jun-08-23 01:20PM
Jun-07-23 07:00AM
May-31-23 07:00AM
May-12-23 11:12AM
May-11-23 04:01PM
May-04-23 02:00AM
May-03-23 04:56PM
07:00AM
08:00AM Loading…
Apr-13-23 08:00AM
Mar-13-23 11:51AM
Mar-08-23 08:32AM
Mar-07-23 04:01PM
Feb-08-23 11:37AM
Feb-06-23 07:00AM
Feb-02-23 07:00AM
Jan-06-23 10:43AM
Jan-05-23 07:00AM
Dec-29-22 02:44PM
Dec-27-22 11:05AM
Dec-01-22 07:00AM
Nov-19-22 07:52AM
Nov-10-22 04:01PM
Nov-01-22 11:53AM
Oct-27-22 07:00AM
Oct-19-22 07:00AM
Sep-21-22 07:00AM
Sep-19-22 07:00AM
Aug-22-22 04:08PM
Akili, Inc. is a digital medicine company, which engages in the development of cognitive treatments through technologies. Its leveraging technologies designed to directly target the brain establishes a new category of medicine that is validated through clinical trials like a drug or medical device, but experienced like entertainment. The company is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Martucci Walter Edward IIChief Executive OfficerSep 11Sale1.052,3532,4713,150,180Sep 14 08:30 AM
Franklin MatthewPresident & COOSep 11Sale1.051,7281,814753,898Sep 14 08:29 AM
Studer JacquelineChief Legal OfficerSep 11Sale1.051,1301,186348,292Sep 14 08:31 AM
Shanbhag SantoshChief Financial OfficerSep 11Sale1.05830872323,636Sep 14 08:28 AM